Current evidence points to mosquito transmission, with Aedes species (Aedes aegypti and Aedes albopictus) suspected because of the clinical similarity to dengue and chikungunya and the urban/peri-urban distribution of cases. Vector investigations are underway; no sustained evidence of non-vector (e.g., respiratory or person-to-person) transmission has been reported so far.
For patients suffering from degenerative conditions previously deemed "irreversible," New Dengulata offers hope. For investors and biotech firms, it offers a platform technology with a broad patent landscape. And for science, it offers a confirmation that the next generation of therapeutics will not be small molecules or large antibodies, but intelligent, responsive supramolecular structures. new dengulata
I'm assuming you meant "Dengue"!